Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
N-C200 series
- Development stage
- Preclinical
- Lead developer
- Neurocarrus
- Modality
- Recombinant Proteins and Enzymes
01
Overview
The `N-C200 series` is a preclinical-stage engineered protein therapeutic being developed by Neurocarrus as a metastatic cancer blocker. The therapeutic is designed using Neurocarrus's proprietary APOLLO targeting and delivery platform, which is based on re-engineered *Clostridium botulinum* toxins. The APOLLO platform typically consists of three modular components: a Translocator (C2II), a Payload (C2I actin remodeler), and a Targeting domain (C1 receptor binder). In the N-C200 series, this platform is utilized to deliver targeted protein therapeutics to block metastatic cancer progression.
- Other names
- N-C200N-C-200N-C 200
Beyond the preview
Go deeper on N-C200 series.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on N-C200 series.